Gastro retentive Ethyl Cellulose Floating Microspheres containing ATENOLOL

Reena Kumari; Nishant Verma; Nidhi Chaudhary; Umesh Kumar; Navneet Thakkar

doi:https://doi.org/10.51976/ijari.321537

Submit Manuscript Login / Register Subscribe

Home Page

Editorial Advisory Board

Mission, Aims & Scope

Current Issue

Gastro retentive Ethyl Cellulose Floating Microspheres containing ATENOLOL

Reena Kumari, Nishant Verma, Nidhi Chaudhary, Umesh Kumar, Navneet Thakkar

Vol 3 , Issue 2 , April - June 2015 | Pages: 209-219 | Research Paper

https://doi.org/10.51976/ijari.321537

Received: April 15, 2015 | Revised: April 30, 2015 | Accepted: May 20, 2015 | Published Online: June 15, 2015

Author Details ( * ) denotes Corresponding author

1. * Reena Kumari, Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India (reenakmit@gmail.com)

2. Nishant Verma, Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India

3. Nidhi Chaudhary, Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India

4. Umesh Kumar, Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India

5. Navneet Thakkar, Department of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India

Controlled release (CR) dosage forms have been extensively used to improve therapy with several important drugs. Incorporation of the drug in a controlled release gastro -retentive dosage forms (CR-GRDF) which can remain in the gastric region for several hours would significantly prolong the gastric residence time of drugs and improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in high pH environment. Several approaches are currently utilized in the prolongation of the GRT, including floating drug delivery systems (FDDS), swelling and expanding systems, polymeric bioadhesive systems, high-density systems, modified-shape systems and other delayed gastric emptying devices. In this review, current & recently developments of Stomach Specific FDDS are discussed that helps to overcome physiological adversities like short gastric residence times and unpredictable gastric emptying times

Keywords

Floating Drug Delivery Systems; Gastric Residence Time; Effervescent; Non Effervescent

Indian Pharmacopoeia., 4th edition, II, Controller of Publication, Govt. of India, New Delhi., 1996, 659

The Merk Index, An Encyclopedia of Chemicals, Drug and Biologicals, 12th edition, Merck Research Laboratories, Division of Merck & Co. INC. Whitehouse Station, NJ. USA. 1996, 8110.

K. D. Tripathi Essentials of Medical Pharmacology; 5th edition; Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 588-598

D. M. Patel, N. M. Patel, V. F. Patel, D. A. Bhatt, Floating Granules of Ranitidine Hydrochloride- Gelucire 43/01: Formulation Optimization Using Factorial Design. AAP

N. Rouge, P. Buri, E. Doelker, Int J Pharm 1996, 136, 117-139. 2) Fell, J.T., Whitehead, L3] Matharu, R.S., Sanghavi, N.M., Drug Dev Ind Pharm 1992, 18, 1567- 1574. 3) Ashford, M., Fell, J.T., Attwood, D., Sharma, H., Woodhead, P.J., Int J Pharm 1993, 95, 193-199.

S. Baumgartner, J. Kristl, F. Vrecer, P. Vodopivec, B. Zorko, Int J Pharm 2000, 195, 125-135. Deshpande, A.A., Rhodes, C.T., Shah, N.H., Malick, A.W., Drug Dev Ind Pharm 1996, 22, 531-539

A. Ateshkadi, N. P. Lam, C. A. Johnson, Clin Pharmacol, 12, 1993, 34-48

H. R. Chueh, H. Zia, C. T. Rhodes, Drug Dev Ind Pharm, 21, 1995, 1725-1747

V. Iannuccelli, G. Coppi, B M.T. ernabei, R. Cameroni, Int J Pharm, 174, 1998, 47-54

R. Talukder, R. Fassihi, Drug Dev Ind Pharm, 30, 2004, 405-412.

S. K. Jain, G.P. Agrawal, N.K. Jain, AAPS Pharm SciTech 2006, 7, E1-., Collet, H., Pharm Technol, 24, 2000, 82-90.S Pharm Sci Tech

F. Atyab, HL Sharma, HAH Mohammad, JT. Fell, In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J Control Release, 42, 1996; 105-108

AK Shrivastava, Wadhwa Saurabh, D. Poonam, Ridhuekar, B. Mishra, Oral sustained delivery of atenolol from floating matrix tablets Formulation and In-vitro evaluation. Drug Development and Industrial Pharmacy. 2005; 31: 367-371

R Talukdar, R. Fassihi Gastroretentive delivery systems: hollow beads. Drug DevInd Pharm, 30, 2004; 405-12

AK Hilton, PB. Deasy In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int J Pharm 1992; 86: 79-88.

PR Seth, J. Tossounian The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Dev Ind Pharm, 10, 1984; 313-39.

SJ Hwang, H Park, K. Park, Gastroretentive delivery systems. Crit Rev Ther Drug Carrier Syst, 15(3), 1998; 243-84

LH Reddy, RS. Murthy Floating dosage system in drug delivery. Crit Rev Ther Drug Carrier Syst, 19(6), 2002, 553-85

PL Bardonnet, V Faivre, WJ Pugh, JC Piffaretti, F. Falson, Gastroretentive dosage forms: overview and special case of Helicibacter pylori. J Control Release, 111, 2006, 1 18.

Y. Kawashima, T. Niwa, H Takenchi, T Hino, Y. Itoh Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci, 81, 1992, 135- 40

L Whiteland, JT Fell, JH. Collett Development of gastroretentive dosage form. Eur J Pharm Sci 1996; 4(suppl.): S182

RM. Harrigan Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 405 5178; 1977

HM Ingani, J Timmermans, A. Moes Conception and in vivo investigation of per oral sustained release floating dosage forms with enhanced gastrointestinal transit. Int J Pharm, 35(12), 1987, 157-64

I. Krogel, R. Bodmeir Floating or pulsatile drug delivery system based on coated effervescent cores. Int J Pharm, 187(2), 1999 175-84

A. Moes Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst, 10, 1993, 143-95

V. Faivre Aspects theoriques de la bioadhesion. In: Falson- Rieg V, Faivre V, Pirot F. ed. Nonvelles forms medicamenteuses , Editions Medicales Internationales, Editions TEC and DOC, Cachan. 2004, 1-24.

Y. Huang, W. Leobandung, A. Foss, NA. Peppas, Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release, 65(1-2), 2000, 63- 71

EA Klusner, E Lavy, M Friedman, A. Hoffman Expandable gasrtroretentive dosage forms. J Control Release, 90(2), 2003, 143-62.

EA Klusner, E Lavy, D Stepensley, M Friedman, A. Hoffman Novel gasrtroretentive dosage form: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res, 19, 2002; 1516-23

LJ Caldwell, CR Gardner, RC. Cargill Drug delivery device which can be retained in the stomach for controlled period of time. US Patent 473 5804, 1988.

LJ Caldwell, CR Gardner, RC Cargill, T. Higuchi, Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 475 8436, 1988

EA Klusner, E Lavy, M Barta, E Cserepes, M. Friedman, A. Hoffman, Novel gasrtroretentive dosage form: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res, 20(9), 2003; 1466-73.

J. Chen, WE Blevins, H Park, K. Park Gastric retention of superporous hydrogel composites. J Control Release, 64(1-3), 2000, 39-51.

J. Chen, K. Park Synthesis and characterization of superporous hydrogel composites. J Control Release, 65(1-2), 2000, 73-82.

G. Chawla, P. Gupta, AK. Bansal Gastroretentive drug delivery systems, Progress in controlled and novel drug delivery systems. CBS Publishers and Distributors. New Delhi. 2004, 76-97

EA. Klusner, S. Eyal, E Lavy, M Friedman, A. Hoffman Novel levodopa gasrtroretentive dosage form: in vivo evaluation in dogs. J Control Release, 88, 2003, 117-26

A. Hoffman Pharmacodynamic aspects of sustained release preparation. Adv Drug Deliv Rev, 33, 1998, 185-99 structures and site-specific surfaces. J Control Release, 65(1-2), 2000, 63- 71